Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies

Clinical trial NCT02629692 · TERMINATED

Trial details

NCT number: NCT02629692
Sponsor: Sun Pharma Advanced Research Company Limited
Status: TERMINATED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Healthy (For Part A)Chronic Myeloid Leukemia (for Part B and C)

Start date: 2016-06-27
Primary completion: 2025-01-03
Enrollment: 124

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.